NSE:NECLIFE
NECTAR LIFESCIENCES LTD.
₹10.86
at close · 21 Sept 2026
Latest filings
- Revised 31st AGM proceedings filed after cut-off date error · Board & Shareholder Meetings
- AGM 2026 voting results: all 5 resolutions passed · Compliance
- Proceedings of 31st AGM held on September 18, 2026 · Board & Shareholder Meetings
- Nectar Lifesciences sets Sep 18, 2026 for 31st AGM; e-voting Sep 15-17 · Board & Shareholder Meetings
- 31st AGM notice published; e-voting Sep 15-17, 2026 · Compliance
- Nectar Lifesciences 31st AGM notice, September 18, 2026 via video conferencing · Board & Shareholder Meetings
- Notice of 31st AGM on September 18, 2026 via video conferencing · Compliance
- Book closure set for 31st AGM, record date Sep 11 2026 · Board & Shareholder Meetings
- Nectar Lifesciences posts Q1 FY27 loss of Rs 13.46 cr, appoints director · Management Changes
- Nectar Lifesciences Q1 FY27 results: net loss of Rs 13.14 cr, board changes · Results
- Board Meeting on Aug 14 to consider Q1 FY26 financial results · Results
- Non-Executive Director Surulichamy Senthilkumar resigns citing personal reasons · Management Changes
- Non-Executive Director Senthilkumar resigns from Nectar Lifesciences board · Management Changes
- Nectar Lifesciences sells Jammu unit land and machinery for 11.22 Cr · Capex & Operations
- Nectar Lifesciences sells Jammu land and plant of idle unit Narbada for INR 11.22 Crore · Strategic Transactions
- Slump sale of Capsule business extended to Dec 31, 2026 · Strategic Transactions
- Nectar Lifesciences extends Empty Hard Gelatin Capsule business sale timeline · Strategic Transactions
- Nectar Lifesciences shifts registered office within Dera Bassi · General
- Nectar Lifesciences shifts registered office within Dera Bassi, effective July 15 · General
- Registrar certificate for dematerialization for Q1 FY27 · Compliance
- Trading Window Closure for Q1 FY27 Results Period · Compliance
- Notice of IEPF transfer of unclaimed shares and FY19 dividend · Compliance
- Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. · Results
- Financial Results for the Year 2025-26 · Results
- Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Financial Results .... · Results
- Update on Slump Sale of Empty Hard Gelatin Capsule Business · Strategic Transactions
- Nectar Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company · Regulatory & Legal
- Please find attached herewith Annual Secretarial Compliance Report for the year ended on March 31, 2026 · Compliance
- Sanjiv Goyal self and Karta of Sanjiv (HUF), Raman Goyal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. · Ownership Changes
- Nectar Lifesciences Limited has informed the Exchange about General Updates · General
- Nectar Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Nectar Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
- Nectar Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company · Regulatory & Legal
- Nectar Lifesciences Limited has informed the Exchange with copy of minutes of Postal Ballot · Board & Shareholder Meetings
- Nectar Lifesciences Limited has informed the Exchange about Intimation of inter-corporate loan agreement with Avensis Exports Private Limited, a Wholly Owned Subsidiary of the Nectar Lifesciences Limited · General
- Nectar Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company · Regulatory & Legal
- Nectar Lifesciences Limited has informed the Exchange about Update on Acquisition · Strategic Transactions
- Nectar Lifesciences Limited has informed the Exchange about updation of disclosures by Nectar Lifesciences Limited as per point no. 1 of its letter no. NLL/CS/2026- 659 dated March 02, 2026. · Compliance
- Nectar Lifesciences Limited has informed the Exchange about Acquisition · Strategic Transactions
- Nectar Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on March 02, 2026. · Board & Shareholder Meetings
- Nectar Lifesciences Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. · Board & Shareholder Meetings
- The Exchange had sought clarification from Nectar Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1.Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. · Regulatory & Legal
- The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(3) and 4(c) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for · Ownership Changes
- Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Nectar Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot · Board & Shareholder Meetings
- sanjiv Goyal, Raman Goyal, Sanjiv (HUF) has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made in reliance upon exemption provided for in regulation 10 of SEBI (SAST) Regulations, 2011. · Ownership Changes
- Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication of Financial Results of the Company for the quarter and nine months ended on December 31, 2025. · Compliance
- We wish to inform you that the board of directors of Nectar Lifesciences Limited ( Company ) in their meeting held on Friday, January 23, 2026, have, inter-alia, noted, decided and approved the following matters:1. Approved the adoption of new set of Memorandum of Association ( MOA ) with amended object clause.2. Appointment of Internal Auditor for the financial year 2025-26 and 2026-27.3. To seek approval of shareholders through postal ballot process for adoption of new set of MOA with amended object clause of the Company.In accordance with the applicable laws and circulars thereunder, the Notice will be sent in electronic mode only to those members whose names appeared in the Register of Members/ List of Beneficial Owners maintained by the Company/ Depositories respectively as at close of business hours on Friday, January 23, 2026 ("Cut-off date"). · Management Changes
- Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025. · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
A listed company listed on NSE and BSE, reporting revenue of ₹5 Cr over the trailing twelve months.
Market Cap
₹211 Cr
P / E (TTM)
—
EV / EBITDA
18.7×
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
2.9%·
ROCE (5y median)
ROE -2.3% · margin —
Leverage
0.00·
Debt / Equity · low
Net debt ₹0 Cr
Revenue FY21→FY26
0.0×▼
Revenue change
₹1,544 Cr → ₹0 Cr
Moves on a normal day
1.75%·
Median daily move
Last 268 sessions · filing days run larger
Scorecard
Measured from the filed financials · as of FY26 — not investment advice
Strengths
Debt at 0.00× equity
Concerns
Erratic profits — up in only 2 of the last 5 years
Returns on capital 2.9% (5-year median)
down from 2.1% in FY21
Charts
How has the market priced it — with filings on the timeline?
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from NECTAR LIFESCIENCES LTD.'s filed financials and exchange disclosures
What does NECTAR LIFESCIENCES LTD. do?
NECTAR LIFESCIENCES LTD. is listed on NSE and BSE, trading under the symbol NECLIFE.
Is NECTAR LIFESCIENCES LTD. profitable?
No. Over the trailing twelve months NECTAR LIFESCIENCES LTD. reported a net loss of ₹245 Cr on revenue of ₹5 Cr.
Does NECTAR LIFESCIENCES LTD. pay a dividend?
Not in the latest reported year — NECTAR LIFESCIENCES LTD.'s dividend payout for FY26 was nil.
Is NECTAR LIFESCIENCES LTD. debt-free?
Effectively yes. Debt stands at 0.00× equity.
How much does the NECTAR LIFESCIENCES LTD. share price move in a day?
On a typical session NECTAR LIFESCIENCES LTD. moves 1.75% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Where can I track NECTAR LIFESCIENCES LTD.'s announcements?
Every NSE and BSE filing by NECTAR LIFESCIENCES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.